tiprankstipranks
Trending News
More News >

Oryzon Genomics Advances Phase III Trial for BPD Treatment

Story Highlights
Oryzon Genomics Advances Phase III Trial for BPD Treatment

Don’t Miss TipRanks’ Half-Year Sale

Oryzon Genomics SA ( (ES:ORY) ) has provided an update.

Oryzon Genomics has submitted the protocol for its Phase III PORTICO-2 clinical trial to the FDA, aiming to evaluate the efficacy of vafidemstat in treating Borderline Personality Disorder (BPD). This trial seeks to address the unmet medical need of aggression in BPD, building on promising results from previous studies, and marks a significant advancement for Oryzon in the neuropsychiatry field.

The most recent analyst rating on (ES:ORY) stock is a Buy with a EUR2.30 price target. To see the full list of analyst forecasts on Oryzon Genomics SA stock, see the ES:ORY Stock Forecast page.

More about Oryzon Genomics SA

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company and a European leader in epigenetics. The company focuses on developing innovative therapies, particularly in the field of neuropsychiatry, using its expertise in epigenetic regulation.

YTD Price Performance: 94.29%

Average Trading Volume: 729,342

Technical Sentiment Signal: Buy

Current Market Cap: €210.8M

For a thorough assessment of ORY stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1